Evidence map›Paper›PMID 39788941›Full record

ArticleSignal transduction and targeted therapy2025

Targeting pathological brain activity-related to neuroinflammation through scRNA-seq for new personalized therapies in Parkinson's disease.

Daniela Mirzac, Manuel Bange, Sebastian Kunz, Phil L de Jager, Sergiu Groppa, Gabriel Gonzalez-Escamilla

Abstract readLetter
In one paragraph

Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daniela MirzacDepartment of Neurology, Universitätsmedizin Mainz and Saarland University Hospital Homburg, Homburg, Germany.
Manuel BangeDepartment of Neurology, Universitätsmedizin Mainz and Saarland University Hospital Homburg, Homburg, Germany.
Sebastian KunzInstitute of Immunology, Universitätsmedizin Mainz, Mainz, Germany.ORCID http://orcid.org/0000-0002-8897-3215
Phil L de JagerCenter for Translational & Computational Neuroimmunology, Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, USA.
Sergiu Groppa *Department of Neurology, Universitätsmedizin Mainz and Saarland University Hospital Homburg, Homburg, Germany.ORCID http://orcid.org/0000-0002-2551-5655
Gabriel Gonzalez-Escamilla *Department of Neurology, Universitätsmedizin Mainz and Saarland University Hospital Homburg, Homburg, Germany. gabriellbk@gmail.com.ORCID http://orcid.org/0000-0002-7209-1736

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39788941
PMCPMC11718261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.